The pharmacodynamics and efficacy of MW151 seen in the discovery approach were reinforced and extended in more detailed studies using genetically modified mouse AD models, and are also consistent with the effects on IL-1β levels reported here. This evidence concerns the gene IL1B and Alzheimer disease.